The sales are small relative to market cap and occurred on the same day at the same price, suggesting coordinated liquidity needs or tax planning rather than negative information. Monitor next 10-Q for any operational deterioration, but this cluster alone does not warrant a bearish read.
Price Chart
Executive Summary
Two C-suite insiders at Oramed Pharmaceuticals sold a combined $226K in open-market sales on the same day, with no indication of 10b5-1 plans. The sales represent ~0.07% of market cap, falling below the 0.1% materiality threshold, suggesting routine portfolio diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- COO & CBO Joshua Hexter sold 30,000 shares at $4.51 for $135K on 2026-10-01
- CFO Avraham Gabay sold 20,000 shares at $4.51 for $90K on 2026-10-01
- Total insider sales of $226K represent approximately 0.07% of market cap
- Both sales were open-market (code S) with no disclosed 10b5-1 plan
Financial Impact
Total insider sales of $226K, approximately 0.07% of market cap
Risk Factors
- Insider selling could accelerate if management perceives headwinds
- No 10b5-1 plan disclosed, leaving open the possibility of opportunistic selling
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORMP-1790975998903 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | Insider Cluster | $4.55 | awaiting T+20 | — | $4.08 (−10.33%) |
Jul 2, 2026 16w ago | Insider Cluster | $4.60 $4.12 | ▼ −10.43% | ▼ −10.02% | $4.08 (−11.30%) |
Jun 30, 2026 16w ago | 8-K | $4.61 $3.97 | ▼ −13.88% | ▼ −11.70% | $4.08 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers